Codagenix is a clinical-stage biotechnology company leading a new era of live vaccines and viral therapeutics. The company's breakthrough platform brings together live-attenuated virus design with cutting-edge codon deoptimization for powerful synthetic biology-based solutions to take on our biggest threats in infectious disease, cancer and animal health. Codagenix was founded based on technology developed in the laboratory of National Academy of Science member Dr. Eckard Wimmer at Stony Brook University; is supported by Adjuvant Capital, TopSpin Partners, and Euclidean Capital; and has ongoing research and license programs with various federal agencies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/15/23 | $25,000,000 | Series B Extension |
Adjuvant Capital Euclidean Capital Serum Institute of India | undisclosed |
